Last reviewed · How we verify
Growth hormone treatment and puberty
Growth hormone treatment stimulates linear growth and metabolic effects during puberty by binding to growth hormone receptors and activating downstream signaling pathways.
Growth hormone treatment stimulates linear growth and metabolic effects during puberty by binding to growth hormone receptors and activating downstream signaling pathways. Used for Growth hormone deficiency in children during puberty, Growth disorders in pediatric patients undergoing pubertal development.
At a glance
| Generic name | Growth hormone treatment and puberty |
|---|---|
| Also known as | Humatrope |
| Sponsor | Baylor College of Medicine |
| Drug class | Growth hormone (recombinant human somatotropin) |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Growth hormone (somatotropin) binds to growth hormone receptors on target tissues, activating JAK-STAT and MAPK signaling cascades that promote protein synthesis, lipolysis, and insulin resistance. During puberty, GH works synergistically with sex steroids to accelerate linear growth velocity, increase lean body mass, and modulate metabolic parameters. The treatment is used to optimize growth outcomes in children with growth hormone deficiency or growth disorders during the pubertal transition.
Approved indications
- Growth hormone deficiency in children during puberty
- Growth disorders in pediatric patients undergoing pubertal development
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Carpal tunnel syndrome
- Gynecomastia
- Fluid retention
Key clinical trials
- Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (PHASE3)
- A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height (PHASE4)
- Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism (PHASE4)
- The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test (NA)
- Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment (PHASE2, PHASE3)
- Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome (PHASE4)
- Saizen in Intra-uterine Growth Retardation (PHASE3)
- Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Growth hormone treatment and puberty CI brief — competitive landscape report
- Growth hormone treatment and puberty updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI